Healthcare / Drug Manufacturers - Specialty & GenericKOSDAQ
$11290.00
-210.00 (-1.83%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 17%
FCF escenarios
weak_data · normalized FCF $-7.6B · quality 39.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
61/100
B
Piotroski
6/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$128.3B
P/E
17.2x
↓EV/EBITDA
8.4x
↓ROE
4.5%
↑Gross Margin
65.3%
↑Debt/Equity
0.44
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+14.3%
FCF CAGR
—
FCF margin
12.1%
FCF / Net income
4.95x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $306.87B · net income $7.48B · FCF $37.01B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $306.87B | $306.87B | $271.12B | $233.68B | $205.39B |
| Net Income | $7.48B | $7.48B | $16.85B | $1.29B | $6.88B |
| EBITDA | $19.25B | $19.25B | $30.94B | $9.43B | $12.47B |
| EPS | 658.00 | 658.00 | 1482.00 | 114.00 | 604.00 |
| Gross Margin | 65.3% | 65.3% | 61.9% | 60.2% | 61.5% |
| Operating Margin | 3.2% | 3.2% | 2.5% | 2.1% | 4.5% |
| Net Margin | 2.4% | 2.4% | 6.2% | 0.6% | 3.3% |
| Balance Sheet | |||||
| Debt/Equity | 0.44 | 0.44 | 0.47 | 0.12 | 0.13 |
| Current Ratio | 1.62 | 1.62 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $37.01B | $37.01B | $-71.39B | $-7.56B | $-1.99B |
| Returns | |||||
| ROE | 4.5% | 4.5% | 10.2% | 0.8% | 4.4% |
| Valuation | |||||
| P/E | 17.16 | 17.16 | 4.47 | 87.19 | 15.58 |
| EV/EBITDA | 8.44 | 8.44 | 4.44 | 10.73 | 8.74 |
| P/B | 0.78 | 0.78 | 0.45 | 0.74 | 0.69 |
| Growth & Yield | |||||
| Revenue Growth | 13.2% | 13.2% | 16.0% | 13.8% | — |
| EPS Growth | -55.6% | -55.6% | 1200.0% | -81.1% | — |
| Dividend Yield | 5.6% | 5.6% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
15.0%
EPS terminal req.
$1001.80
Spread vs growth
-70.6%
5Y implied EPS CAGR
13.0%
EPS terminal req.
$1212.18
Spread vs growth
-68.6%
10Y implied EPS CAGR
11.5%
EPS terminal req.
$1952.22
Spread vs growth
-67.1%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+63.1%
Start / end P/E
4.8x → 17.2x
EPS bridge
1482.00 → 658.00
Residual
-141.6%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.